LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

34.77 -3.15

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

34.4

Max

Schlüsselkennzahlen
By Trading Economics
Einkommen	-22M -102M
Angestellte	258
EBITDA	-30M -109M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+45.25% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	4. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	666M 6.3B
Vorheriger Eröffnungskurs	37.92
Vorheriger Schlusskurs	34.77

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Mai 2026, 23:58 UTC

Ergebnisse

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7. Mai 2026, 22:57 UTC

Ergebnisse

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7. Mai 2026, 23:52 UTC

Ergebnisse

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7. Mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7. Mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7. Mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7. Mai 2026, 23:11 UTC

Ergebnisse

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7. Mai 2026, 23:06 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7. Mai 2026, 23:05 UTC

Ergebnisse

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7. Mai 2026, 23:04 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7. Mai 2026, 23:03 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7. Mai 2026, 23:03 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7. Mai 2026, 23:02 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7. Mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7. Mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7. Mai 2026, 22:42 UTC

Ergebnisse

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7. Mai 2026, 22:33 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7. Mai 2026, 22:32 UTC

Ergebnisse

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7. Mai 2026, 22:31 UTC

Ergebnisse

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7. Mai 2026, 22:31 UTC

Ergebnisse

Macquarie: 68% of FY Income From International >MQG.AU

7. Mai 2026, 22:30 UTC

Ergebnisse

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7. Mai 2026, 22:30 UTC

Ergebnisse

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7. Mai 2026, 22:29 UTC

Ergebnisse

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7. Mai 2026, 22:28 UTC

Ergebnisse

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7. Mai 2026, 22:28 UTC

Ergebnisse

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7. Mai 2026, 22:27 UTC

Ergebnisse

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7. Mai 2026, 22:27 UTC

Ergebnisse

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7. Mai 2026, 22:26 UTC

Ergebnisse

Macquarie to End Share Buyback Extended in November>MQG.AU

7. Mai 2026, 22:25 UTC

Ergebnisse

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

45.25% Vorteil

12-Monats-Prognose

Durchschnitt 52.1 USD 45.25%

Hoch 64 USD

Tief 35 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.